Held by 4 specialist biotech funds
High Convergence# Signal Note: Perceptive Advisors Initiates TNGX Position **Summary:** Edelman's team established a $4.5M stake in Tango Therapeutics, a synthetic lethality-focused oncology company.
AI analyst context — unlock full analysis
# Signal Note: RTW Investments Initiates $13.2M Position in TNGX RTW's entry into Tango signals conviction in the company's synthetic lethality platform, likely driven by upcoming catalysts in its pipeline—particularly SL-279252 (KRAS G12C/G12V synthetic lethal) and early-stage programs targeting difficult-to-drug mutations in colorectal and pancreatic cancers. The $13.2M stake (~2% of market cap) reflects a meaningful but measured conviction level, suggesting RTW sees clinical or partnership validation risk/reward as favorable near-term.
+ 2more — see how much conviction went in
See the Full Story**Insider Sale — Tango Therapeutics (TNGX)** Crystal Adam, President of R&D, sold 12,000 shares at $20.11 for ~$241K. R&D head sales always warrant attention, but this is a relatively modest disposal and could reflect routine liquidity, diversification, or pre-planned 10b5-1 activity — worth checking the filing for context. Monitor whether this is isolated or part of a cluster of insider sells, which would be more meaningful signal ahead of any clinical readouts.